Two-year toxicity of simultaneous integrated boost in hypofractionated prone breast cancer irradiation: Comparison with sequential boost in a randomized trial. (May 2021)

• Record Type: Journal Article
• Authors: Van Hulle, Hans; Desaunois, Eline; Vakaet, Vincent; Paelinck, Leen; Schoepen, Max; Post, Giselle; Van Greveling, Annick; Speleers, Bruno; Mareel, Marc; De Neve, Wilfried; Monten, Chris; Deseyne, Pieter; Veldeman, Liv
• Is Part Of: Radiotherapy and oncology. Volume 158(2021)
• Page Start: 62
• Page End: 66
• Publication Date: 2021-05
• Subjects: Breast cancer boost -- Simultaneous ingetrated boost -- Sequental boost; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2021.02.010
• Languages: English
• ISSNs: 0167-8140

Abstract

Highlights: No differences in physician-assessed two-years toxicity between an integrated and sequential boost can be found. Photographic analysis shows no differences between an integrated and sequential boost. A simultaneous integrated boost does not lead to an excess in outcome at 2 years. Abstract: Introduction: A simultaneous integrated boost (SIB) leads to less acute toxicity. Less is known for late toxicity due to SIB. In this first and only randomized trial, two-years toxicity is analysed. Materials and methods: Physician-assessed toxicity, using the LENT SOMA scale, and photographs, analysed with the BCCT.core software, was examined for 150 patients, randomized between SIB and sequential boost (SEB). Results: Differences in physician-assessed two-years toxicity and photographic analysis between SIB and SEB are very small and not significant. Conclusion: There is no indication that a SIB leads to an excess in toxicity or worse cosmetic outcome at 2 years.